Evolving our approach to access in Upper Middle-Income Countries
ViiV Healthcare is fundamentally committed to increasing access to dolutegravir (DTG) in line with WHO guidelines as part of our mission to leave no person living with HIV behind. To continue to meet the ever-changing needs of people living with HIV around the world and following on from extensive conversations with key stakeholders including governments, NGOs and members of the HIV community, we have continued to take steps to evolving our approach to access.
At the end of 2019 we took a first step by enabling GSK, our distributor in certain Upper Middle-Income Countries (UMIC), to offer a reduced price for our DTG-based medicines in these countries. As a next step, we are actively negotiating the terms of a new voluntary licence agreement with the Medicines Patent Pool (MPP). This new agreement aims to enable generic manufacturers with a licence to provide access to generic DTG-based formulations for people living with HIV in four UMICs; Azerbaijan, Belarus, Kazakhstan and Malaysia.*
The proposed voluntary licence agreement will set a maximum price at which generic licensees are able to sell DTG in any of these four countries, and this price would be expected to decrease as the country enables increased access to DTG for people living with HIV in that country. Providing an innovative and sustainable approach to access for our HIV medicines is a priority for us and together with the MPP, we are working as quickly as possible to implement this new voluntary licence agreement for these countries.
As a company 100% focused on the needs of people living with HIV, making our medicines as widely available to patients regardless of income or where they live is central to both our access to medicines strategy and a core element of our corporate strategy.
Click here to learn more about our access to medicines strategy and commitments.